PrEP

Small, automated financial incentives improved retention in care and viral suppression among adults with HIV starting antiretroviral therapy.

Results were announced at the virtual 23rd International AIDS Conference.

In developing countries with overcrowded hospitals, community pharmacies can relive burden, help patients adhere to their regimen, thus offering a viable alternative to patients who need to maintain their medication and keep stable.

PrEP-AP is intended to lower out-of-pocket costs for both uninsured and insured people who are eligible for PrEP services such as laboratory tests.

When taken daily, PrEP is highly effective for preventing HIV from sex or injection drug use.

New research indicates that even with effective antiretroviral treatment, HIV may still affect the central nervous system.

Remdesivir, the investigational drug for the treatment of the coronavirus disease 2019 (COVID-19), will be sold for $390 per vial.

Although researchers know that HIV enters the brain within 8 days of infection, less is known about whether HIV-infected brain cells can release the virus, letting it migrate from the brain back into the body to infect other tissues.

Access and adherence to pre-exposure prophylaxis is vital in eradicating the HIV epidemic in the United States.

Closing these gaps in care could improve access for those worse affected by HIV in developing countries.

HIV drug prices rose 34% between 2012 and 2018 and continue to climb, which experts say is a huge issue.

Uptake of PrEP has been slow, particularly among at-risk individuals between 13-19 years of age ar risk for HIV infection.

Pharmacy Times® interviewed James Krellenstein, co-Founder, PrEP4All Collaboration and Organizer, The COVID-19 Working Group, to discuss the development of PrEP for the COVID-19 pandemic.

As we consider the implications of the COVID-19 pandemic and the release of remdesivir, ICER’s expedited evaluation raises some questions related to value-based pricing evaluations.

Adverse events included self-limited nausea and diarrhea with no difference between the 2 groups.

Despite the rate of HIV infection in adolescents and young adults, a study found that PrEP awareness is limited.

A new report from PrEP4All Collaboration warned that current research efforts aimed at controlling the COVID-19 pandemic are missing an important area of research into PrEP.

Leronlimab has been granted 2 other Fast Track designations as a combination therapy with HAART for HIV and as a treatment for metastatic triple-negative breast cancer.

On April 24, the CDC published some considerations for clinical providers who are evaluating adolescents for treatment with PrEP.

The study sought to determine the role of HIV related medical mistrust, and willingness to use PrEP among black women in the United States.

Researchers may be able to isolate reservoir cells from patients using the CD127 protein, which would make it possible to study what allows the cells to silence and reactivate the virus .

Emtricitabine 200 mg and tenofovir alafenamide 25 mg tablets, F/TAF (Descovy, Gilead) was just as effective as emtricitabine 200 mg and tenofovir disoproxil fumarate 300 mg F/TDF (Truvada).

Hydroxychloroquine and remdesivir have been caught up in the rush to develop an effective treatment for COVID-19.

A new study showed that most women living with HIV that were interviewed preferred long-acting injectable adherence to antiretroviral therapy over daily pills.

Implementation of adherence programs can be effective in improving outcomes for patients and reduce costs both at the patient and systemic level.

Widely used medications for patients with HIV/AIDS may be potential treatments for the coronavirus disease 2019 should the drugs demonstrate safety and efficacy in clinical trials.

The antiviral drug remdesivir has been shown by researchers to effectively stop the replication mechanism of SARS-CoV-2 that causes COVID-19, according to a new study.

Remdesivir is not yet licensed or approved anywhere internationally and has not been demonstrated to be safe or effective for the treatment of COVID-19.

The findings showed that non-SCD congenital anemia diagnosis was associated with a higher risk of HIV acquisition compared with SCD, according to the study authors.

The objective of the study was to determine whether there was an association between PrEP use and decreases in HIV diagnoses.